Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance Personalized Cancer Care in China
April 26 2018 - 6:00PM
Business Wire
--DIAN Designated Roche’s and Foundation
Medicine’s Exclusive Clinical Sequencing Partner in China--
--Roche will Commercialize Foundation
Medicine’s Comprehensive Genomic Profiling Tests in China--
Foundation Medicine, Inc., (NASDAQ:FMI), F. Hoffmann-La Roche
Ltd (Roche) and DIAN Diagnostics Group, Co., Ltd. (DIAN), today
announced a three-party collaboration to integrate Foundation
Medicine’s comprehensive genomic profiling (CGP) assays into
clinical patient care in mainland China. Under the
collaboration:
- DIAN, a leader in the development and
supply of Chinese medical diagnostic products and services, becomes
the exclusive clinical sequencing partner in China for
FoundationOne®, FoundationACT® and FoundationOne®Heme, enabling the
delivery of personalized cancer care for patients.
- Roche maintains commercial exclusivity
for Foundation Medicine’s molecular information products in China,
and in cooperation with DIAN continues its current in-county
activities to support the broad integration of CGP into clinical
care.
Cancer is the leading cause of death
among China's population of 1.4 billion. In 2015, there
were approximately 4.3 million new cancer cases and more than 2.8
million cancer deaths in China1. Given the high volume of new
and emerging oncology research, new innovations in diagnostics and
the country’s national focus on personalized care, there is a need
for molecular information services that enable oncologists to
efficiently match patients to cancer therapies based on the
molecular blueprint of each individual’s tumor.
“Healthcare is transforming at a rapid pace in China and there
is a national urgency to develop strategies that can advance
personalized medicine to improve clinical outcomes for patients,”
said Mr. Haibin Chan, Chairman of DIAN Diagnostics. “The
integration of analytically-validated CGP tests into clinical
practice is critical to inform patient treatment options, including
determining eligibility for many clinical trials. We believe the
combination of DIAN’s diagnostics expertise and market leadership,
Roche’s commercial expertise, paired with Foundation Medicine’s
leadership in molecular information, will assist China in taking a
significant step forward toward achieving its national goal of
widespread patient access to precision medicine.”
DIAN is one of the leading independent medical laboratories in
China and is dedicated to innovation in diagnostic testing
platforms. Importantly, DIAN is one of the first commercial
laboratories approved by the National Health Commission of China to
receive a next generation sequencing (NGS) pilot license for cancer
diagnostics. DIAN’s diagnostic network stretches to more than 30
laboratories, covering almost all of mainland China, processing
more than 100,000 clinical samples per day. To advance clinical
diagnostics in China, DIAN has also established “precision
treatment centers” with medical institutions and hospitals.
“DIAN’s sequencing expertise and its broad healthcare network
will enable CGP as a critical component of patient clinical care in
China,” stated Melanie Nallicheri, chief business officer and head,
biopharma for Foundation Medicine. “Accelerating patient access to
precision medicine approaches is critical to China’s oncology
community and we’re delighted that our participation in this effort
supports Foundation Medicine’s presence, differentiation and
patient impact globally.”
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information
company dedicated to a transformation in cancer care in which
treatment is informed by a deep understanding of the genomic
changes that contribute to each patient's unique cancer. The
company offers a full suite of comprehensive genomic profiling
assays to identify the molecular alterations in a patient's cancer
and match them with relevant targeted therapies, immunotherapies
and clinical trials. Foundation Medicine’s molecular information
platform aims to improve day-to-day care for patients by serving
the needs of clinicians, academic researchers and drug developers
to help advance the science of molecular medicine in cancer. For
more information, please visit http://www.FoundationMedicine.com or
follow Foundation Medicine on Twitter (@FoundationATCG).
About DIAN
DIAN Diagnostics Group Co., Ltd. is one of the leading
diagnostic companies in China, focusing on the business of
independent clinical diagnosis service. DIAN’s diagnostic network
in China stretches to more than 38 laboratories, covering every
province of mainland China. DIAN is serving more than 15,000
medical institutions in China.
DIAN is committed to providing a “Total Solution of Medical
Diagnosis Service” for its customers, with the business segment
covering medical diagnosis services, IVD products, cold-chain
logistics, forensic expertise, CRO business and other medical
diagnostic related fields. With the mission of “Equal Access to
Healthcare”, DIAN is committed to create a health industrial eco
system and achieve multiple-wins for medical institutions,
government and people.
Foundation Medicine®, FoundationOne®, FoundationACT® and
FoundationOne®Heme are registered trademarks of Foundation
Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements for
Foundation Medicine
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding a
collaboration among Foundation Medicine, Roche, and DIAN; the
ability of the collaboration to accelerate the integration of
Foundation Medicine’s CGP assays into clinical care of patients or
patient access to precision medicine in China; and the ability of
the collaboration to expand Foundation Medicine’s presence,
differentiation and patient impact globally. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
the risk that the parties are unable to successfully implement the
collaboration and commercialize Foundation Medicine’s CGP assays in
China; the risk that the collaboration does not proceed as
expected; the risk that the collaboration does not meet the
objectives of the parties; and the risks described under the
caption "Risk Factors" in Foundation Medicine's Annual Report on
Form 10-K for the year ended December 31, 2017, filed with the
Securities and Exchange Commission on March 7, 2018, as well as
other risks detailed in Foundation Medicine's subsequent filings
with the Securities and Exchange Commission. All information in
this news release is as of the date of the release, and Foundation
Medicine undertakes no duty to update this information unless
required by law.
1 W. Chen et al., CA Cancer J. Clin. 66, 115–132
(2016).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180426006529/en/
For Foundation MedicineMedia:Lee-Ann Murphy,
617-245-3077pr@foundationmedicine.comorInvestors:Kimberly
Brown, 617-418-2215ir@foundationmedicine.com
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Jul 2023 to Jul 2024